bioAffinity Technologies Inc. (BIAF) Net Asset Value

bioAffinity Technologies (BIAF) generates revenue through the sale of CyPath, rapid tests for the early detection of tumors targeting smokers. The business efficiency relies on a streamlined express delivery system for diagnostic kits to medical centers. bioAffinity Technologies (BIAF) develops non-invasive screening methods to reduce global mortality, with the indicator standing at 0.01. This price chart for the shares on the GURU.Markets platform allows for tracking the dynamics of this medical startup.

For bioAffinity Technologies (BIAF), the fundamental value of assets depends directly on the commercialization of lung cancer tests and FDA approvals. The company's book value of equity measures the difference between all assets and liabilities, demonstrating the real value of equity stripped of market noise. Analyzing this metric allows for the determination of the business's intrinsic resilience and the quality of resource management during the scaling of laboratories.